Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and exposure of SB-751689 when administered
alone at supratherapeutic doses and when SB-751689 is co administered with ketoconazole, a
PGP/CYP3A4 inhibitor that increases exposure of SB-751689. Data from this study will enable
the planning and conduct of a QTc study for SB-751689.